Sanofi India Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹420Cr
- −18.4% YoY
- Net profit
- ₹62Cr
- −31.9% YoY
- Margin
- 22%
- −1 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Partnership sales are expected to stabilize by end of 2026, despite continued fluctuations due to stock replenishment cycles. Sanofi India aims for continued double-digit growth in diabetes, especially powered by insulin and the Soliqua portfolio.
From Sanofi India Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Partnership sales are expected to stabilize by end of 2026, despite continued fluctuations due to stock replenishment cycles.
- Diabetes portfolio is growing consistently, with insulin segment showing 6% full-year growth and double-digit growth in Q4 2025.
- Partnered portfolio volume growth is estimated at around 4%, with price increases linked to WPI for controlled products and up to 10% for others.
- Soliqua (GLP-1 and glargine combo) and Toujeo (U-300 glargine) hold growth potential with plans to accelerate double-digit growth.
2 more points from Sanofi India Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sanofi India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The focus is on business model transformation, partnerships, operational efficiency, and growth in insulin and diabetes segments.
- No new product launches planned for 2026, but focus on real-world evidence publications and expansion of existing products (Soliqua, Toujeo) in the public sector.
- Considerations are ongoing for introducing reusable pens for Soliqua in future years (FY '27 or FY '28), reflecting potential future strategic investment.
- Overall, the company is focusing on stabilization, growth through partnerships, and digital/AI-enabled capabilities rather than announcing specific capital expenditure plans at this time.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sanofi India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Sanofi India Ltd said on order book & pipeline — free account, 30 seconds.
Sanofi India Ltd — Quarterly revenue & net profit
Sanofi India Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 420 | 515 | -18.4% | 475 | -11.6% |
| Operating profit (EBITDA) | 90 | 118 | -23.7% | 134 | -32.8% |
| Operating margin | 22% | 23% | -1 pp | 28% | -6 pp |
| Profit before tax | 83 | 122 | -32% | 102 | -18.6% |
| Net profit (PAT) | 62 | 91 | -31.9% | 76 | -18.4% |
| EPS (₹) | 26.83 | 39.70 | -32.4% | 33.04 | -18.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹492 Cr, net profit ₹117 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sanofi India's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sanofi India Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sanofi India Ltd Q3 FY26 results?
Partnership sales are expected to stabilize by end of 2026, despite continued fluctuations due to stock replenishment cycles. Sanofi India aims for continued double-digit growth in diabetes, especially powered by insulin and the Soliqua portfolio.
What is Sanofi India Ltd share price analysis?
Sanofi India Ltd currently shows a neutral. The stock trades at a P/E of 21.8 with a market cap of ₹7,468 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Sanofi India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.